-
Innovation Ranking
NewInnovation Ranking – Laboratorios Farmaceuticos Rovi SA
Laboratorios Farmaceuticos Rovi SA (Rovi), a subsidiary of Norbel Inversiones SL, is a pharmaceutical company that carries out the research, development, manufacturing, and marketing of prescription and hospital products. The company's product portfolio includes licensed prescription pharmaceuticals in the therapeutic areas of cardiovascular, osteoarticular, thrombosis, pneumology, gynecology, central nervous system (CNS), endocrinology, oncology, and urology; diagnostic imaging products include contrast agents and injection systems for imaging procedures such as computed tomography, X-rays, magnetic resonance imaging and ultrasound screening; products for...
-
Company Insights
Innovation and Patenting activity of Laboratorios Farmaceuticos Rovi SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Laboratorios Farmaceuticos Rovi SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Letrozole in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Letrozole in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Letrozole in Breast Cancer Drug Details: Letrozole (Letrozole Quarterly) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gebasaxturev in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gebasaxturev in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gebasaxturev in Hypopharyngeal Cancer Drug Details: Cavatak (Coxsackievirus A21, CVA-21) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Epcoritamab in Burkitt Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Epcoritamab in Burkitt Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Epcoritamab in Burkitt Lymphoma Drug Details: Epcoritamab-Bysp (Epkinly / Tepkinly) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Codeine + Dipyrone) in Post-Operative Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Codeine + Dipyrone) in Post-Operative Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Codeine + Dipyrone) in Post-Operative Pain Drug Details: The fixed...
-
Product Insights
Macular Edema – Drugs In Development, 2023
Global Markets Direct’s, ‘Macular Edema - Drugs In Development, 2023’, provides an overview of the Macular Edema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Glaucoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Glaucoma - Drugs In Development, 2023’, provides an overview of the Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Leiomyoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Leiomyoma - Drugs In Development, 2023’, provides an overview of the Leiomyoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leiomyoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...